CHARMA Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Data Collection
Crohn Disease+3
+ Digestive System Diseases
+ Gastroenteritis
Treatment Study
Summary
Study start date: July 1, 2003
Actual date on which the first participant was enrolled.The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.854 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion: * Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of \>= 220 and \<= 450, normal laboratory parameters, * are willing and able to give informed consent, and * are able to self-inject or have a designee or healthcare professional who can inject the study medication. Exclusion: * History of certain types of cancer, diagnosis of ulcerative colitis, * female or breast feeding subjects, * surgical bowel resection(s) with in the past 6 months, * history of listeria, * human immunodeficiency virus (HIV), * central nervous system demyelinating disease or untreated TB, * history of a poorly controlled medical condition, * unsuccessful response to infliximab or any anti-TNF agent use in the past.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 43 locations
Thornton Hospital Reumatology Division
La Jolla, United StatesOpen Thornton Hospital Reumatology Division in Google MapsUCSF San Francisco General Hospital
San Francisco, United StatesCal-West, Inc.
San Francisco, United StatesWestern States Clinical Research
Arvada, United States